Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells

Annals of Hematology

Volumn 88, Issue 6, 2009, Pages 573-580

  de Jonge Peeters, Susan D P W M ^a   van der Weide, Karen ^a   Kuipers, Folkert ^a   Sluiter, Wim J ^a   de Vries, Elisabeth G E ^a   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ABC transporters; AML; CD34 subpopulations; Cholesterol metabolism; Cytostatic agents

Indexed keywords

CYTARABINE; DAUNORUBICIN; MEVINOLIN; CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; CD34+ T LYMPHOCYTE; CELL COUNT; CELL HETEROGENEITY; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG POTENCY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; APOPTOSIS; CELL CULTURE; CELL SEPARATION; DRUG EFFECT; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD34; APOPTOSIS; CELL SEPARATION; CELLS, CULTURED; HUMANS; LEUKEMIA, MYELOID, ACUTE; LOVASTATIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 67651056506     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0633-2     Document Type: Article

References (24)

1. Peeters SD, van der Kolk DM, de Haan G, Bystrykh L, Kuipers F, de Vries EG et al (2006) Selective expression of cholesterol metabolism genes in normal CD34+CD38- cells with a heterogeneous expression pattern in AML cells. Exp Hematol 34:622-630 doi: 10.1016/j.exphem.2006.01.020
2. de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de Witte TJ et al (2006) Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+. Leukemia 20:750-754 doi: 10.1038/sj.leu.2404131
3. Wong J, Quinn CM, Brown AJ (2004) Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol 24:2365-2371 doi: 10.1161/01.ATV.0000148707.93054.7d
4. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE (2003) Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101:3628-3634 doi: 10.1182/blood-2002-07-2283
5. Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA (2004) Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 104:1816-1824 doi: 10.1182/blood-2004-01-0395
6. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH et al (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 93:1308-1318
7. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ (2004) Blocking the Raf/ MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64:6461-6468 doi: 10.1158/ 0008-5472.CAN-04-0866
8. Minden MD, Dimitroulakos J, Nohynek D, Penn LZ (2001) Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 40:659-662 doi: 10.3109/ 10428190109097663
9. Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE (2003) Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 27:133-145 doi: 10.1016/S0145-2126(02)00085-1
10. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S et al (2007) Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high dose Ara-C: A phase 1 study. Blood 109:2999-3006
11. van Gosliga D, Schepers H, Rizo A, van der Kolk D, Vellenga E, Schuringa JJ (2007) Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. Exp Hematol 35:1538-1549 doi: 10.1016/j.exphem.2007.07.001
12. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
13. Schepers H, van Gosliga D, Wierenga AT, Eggen BJ, Schuringa JJ, Vellenga E (2007) STAT5 is required for long-term maintenance of normal and leukemic humanstem/progenitor cells. Blood 110:2880-2888 doi: 10.1182/ blood-2006-08-039073
14. SPSS for Windows, Rel. 14.0.0. 2005. Chicago: SPSS Inc.
15. Lowenberg B, Boogaerts MA, Daenen SM, Verhoef GE, Hagenbeek A, Vellenga E et al (1997) Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 15:3496-3506
16. Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF et al (2004) The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 103:2908-2913 doi: 10.1182/ blood-2003-07-2195
17. Daenen SM, de Wolf JThM, Vellenga E, van Imhoff GW, van den Berg-de Ruiter E, Smit JW (2001) 6-Mercaptopurine, still valuable for the palliative treatment of acute myeloid leukemia. Hematol 6:231-40
18. Breems DA, Boogaerts MA, Dekker AW, van Putten WL, Sonneveld P, Huijgens PC et al (2005) Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: A prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 128:59-65 doi: 10.1111/j.1365-2141.2004.05282.x
19. Guan Y, Gerhard B, Hogge DE (2003) Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101:3142-3149 doi: 10.1182/ blood-2002-10-3062
20. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E (2007) ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 62:214-226 doi: 10.1016/ j.critrevonc.2007.02.003
21. Bonnet D, Dick JE (1997) Human acute myeloid leukaemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737 doi: 10.1038/nm0797-730
22. Zhang FL, Casey PJ (1996) Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269 doi: 10.1146/ annurev.bi.65.070196.001325
23. Du W, Prendergast GC (1999) Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 59:5492-5496
24. Blanco-Colio LM, Justo P, Daehn I, Lorz C, Ortiz A, Egido J (2003) Bcl-xL overexpression protects from apoptosis induced by HMG-CoA reductase inhibitors in murine tubular cells. Kidney Int 64:181-191 doi: 10.1046/j.1523-1755.2003.00080.x